Eli Lilly Net Change in Short-term Investments 2010-2025 | LLY
Eli Lilly annual/quarterly net change in short-term investments history and growth rate from 2010 to 2025. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Eli Lilly net change in short-term investments for the quarter ending March 31, 2025 was $0M, a 0% increase year-over-year.
- Eli Lilly net change in short-term investments for the twelve months ending March 31, 2025 was $0.116B, a 47.36% decline year-over-year.
- Eli Lilly annual net change in short-term investments for 2024 was $0.05B, a 46.38% decline from 2023.
- Eli Lilly annual net change in short-term investments for 2023 was $0.094B, a 571.43% increase from 2022.
- Eli Lilly annual net change in short-term investments for 2022 was $0.014B, a 138.78% decline from 2021.
Eli Lilly Annual Net Change in Short-term Investments
(Millions of US $) |
| 2024 |
$50 |
| 2023 |
$94 |
| 2022 |
$14 |
| 2021 |
$-36 |
| 2020 |
$118 |
| 2019 |
$94 |
| 2018 |
$2,440 |
| 2017 |
$1,463 |
| 2016 |
$315 |
| 2015 |
$1,320 |
| 2014 |
$2,416 |
| 2013 |
$1,789 |
| 2012 |
$375 |
| 2011 |
$-251 |
| 2010 |
$-687 |
| 2009 |
$399 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$707.068B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
